To explore the neuroprotective mechanisms of terpenoids, including their modulation of inflammation, mitigation of oxidative stress, regulation of apoptotic pathways, and promotion of neurogenesis, a wide variety of naturally occurring chemicals, known as terpenoids, have shown promise as neuroprotective agents for the treatment of Parkinson's disease (PD). In this paper, we summarize known methods, which include reducing oxidative stress, enhancing neurogenesis and neurotrophic factors, and modulating apoptotic signaling. In preclinical models of Parkinson's disease, compounds such as triptolide, andrographolide, carnosic acid, betulinic acid, and asiatic acid have demonstrated significant efficacy by modulating critical pathways, including the Nrf2/ARE, PI3K/Akt, and NF-κB pathways. In addition, terpenoids show potential as a treatment for PDrelated symptoms, such as impaired mitochondrial activity, protein misfolding, and blood-brain barrier breakdown. Although terpenoids have demonstrated some research potential, their limited target selectivity, poor solubility, and low bioavailability still hinder their clinical application. The primary objectives of future research should be to enhance formulations, explore methods for incorporating terpenoids into conventional pharmacotherapies, and investigate innovative drug delivery systems. Individualized PD therapy may be transformed by terpenoid-based personalized medicine techniques, in addition to genetics and high-throughput screening. Terpenoids should only be considered as a possible treatment option for PD after rigorous clinical trials that clarify pharmacokinetics and safety characteristics.
Sharma et al. (Sat,) studied this question.